TNF blockers and hepatosplenic T-cell lymphoma linked
FDA has received reports of hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease and ulcerative colitis being treated with tumor necrosis factor blockers, azathioprine, and mercaptopurine.
FDA has received reports of hepatosplenic T-cell lymphoma (HSTCL), a rare, aggressive cancer of white blood cells that usually is fatal, in adolescents and young adults with Crohn's disease and ulcerative colitis being treated with tumor necrosis factor (TNF) blockers (ie, infliximab, etanercept, adalimumab, certolizumab pegol, and golimumab), azathioprine, and mercaptopurine.
Several cases have occurred in patients being treated for rheumatoid arthritis and in 1 patient with psoriasis.
Although HSTCL was reported most often in those patients receiving a combination of medicines that suppress the immune system, including the TNF blockers, azathioprine, and/or mercaptopurine, there were some reports of HSTCL in patients who received azathioprine or mercaptopurine as monotherapies.
Overcoming pediatric obesity: Behavioral strategies and GLP-1 support
October 4th 2024Kay Rhee, MD, discusses the challenges of pediatric obesity treatment, highlighting the role of biological and environmental factors, behavioral interventions, and the potential benefits of GLP-1 medications in weight management for children and teens.
Trend talk: Increasing THC ingestions in pediatric emergency departments
October 4th 2024At the 2024 AAP National Conference, Steven Selbst, MD, highlighted the rise in accidental THC ingestions among children, urging pediatricians to counsel parents on the dangers of improperly stored THC gummies that resemble candy.
